Vistagen Therapeutics Clinical Trial Data
Vistagen presented positive exploratory data at Psych Congress 2026 showing that its Phase 3 candidate fasedienol (PH94B) demonstrated statistically significant improvements in anxiety symptoms for patients with very severe social anxiety disorder. The findings, derived from post-hoc and prespecified subpopulation analyses of the PALISADE-4 and Phase 2a RDS trials, suggest that fasedienol may provide rapid-onset relief and that a second dose could further improve anticipatory anxiety.